Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return

Simply Wall St

Mon, February 23, 2026 at 1:23 PM GMT+9 3 min read

In this article:

IMVT

+0.91%

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Why Immunovant (IMVT) is on investors’ radar

Immunovant (IMVT), a clinical stage immunology company focused on monoclonal antibody treatments for autoimmune diseases, has drawn attention recently as investors reassess its pipeline progress and share performance over the past month and the past three months.

See our latest analysis for Immunovant.

At a share price of $26.60, Immunovant’s recent 7 day share price return of 3.30% and 90 day share price return of 14.07% sit alongside a 1 year total shareholder return of 25.06%. This performance may indicate momentum building around its clinical pipeline story.

If Immunovant’s move has you looking at other health focused names, our screener of 27 healthcare AI stocks is a straightforward way to find more ideas in this space.

With the share price at $26.60 and a 1 year total shareholder return of 25.06%, plus a published analyst price target of $41.13, you have to ask: is Immunovant still undervalued, or is the market already pricing in future growth?

Preferred Price to Book of 5.5x: Is it justified?

On a P/B of 5.5x at a last close of $26.60, Immunovant trades at a higher level than many investors might expect for a company with no current revenue and ongoing losses.

P/B compares the market value of the company to its book value, which is essentially the net assets on the balance sheet. For a clinical stage biotech like Immunovant with $0 revenue and a reported net loss of $464.199 million, the ratio often reflects how much the market is willing to pay today for a pipeline that has not yet begun to generate sales.

Relative to similar sized peers, Immunovant is described as good value on this measure, with its 5.5x P/B lower than the peer average of 13.8x. That suggests investors in comparable companies are, on average, paying more per dollar of net assets than the current pricing here. However, compared to the broader US Biotechs industry average of 2.6x, Immunovant sits at a premium, which points to the market assigning a richer valuation than for the sector overall.

Put simply, against close peers the P/B looks restrained, while against the industry it looks expensive. Any view on whether 5.5x is reasonable rests on how you weigh those two comparison points and how you think about a business that is forecast to grow revenue quickly but remain unprofitable.

See what the numbers say about this price — find out in our valuation breakdown.

La historia continúa  

Result: Price to book ratio of 5.5x (ABOUT RIGHT)

However, that story can change quickly if key trials disappoint or if ongoing losses of $464.199 million force earlier than expected fundraising on less favorable terms.

Find out about the key risks to this Immunovant narrative.

Next Steps

All of this leaves mixed sentiment, with both risks and rewards on the table. It makes sense to move quickly and review the details yourself, starting with 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If Immunovant has caught your attention, do not stop here, the Simply Wall St Screener can quickly surface other stocks that fit the kind of portfolio you want to build.

Target steady compounders with 87 resilient stocks with low risk scores that aim to keep volatility in check while still giving you meaningful exposure to the market.

Spot tomorrow’s potential standouts early by scanning our screener containing 23 high quality undiscovered gems before they appear on everyone else’s watchlist.

Build a core of resilient holdings using the solid balance sheet and fundamentals stocks screener (43 results) so you are not relying on fragile financial foundations.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include IMVT.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Condiciones y Política de privacidad

Privacy Dashboard

More Info